-
公开(公告)号:US20240325413A1
公开(公告)日:2024-10-03
申请号:US18577390
申请日:2022-07-07
申请人: 484 Science Corp
CPC分类号: A61K31/658 , A61K9/0075 , A61K9/008 , A61K31/40 , A61K31/4704 , A61K45/06 , A61K47/06
摘要: The present invention provides formulations for inhalation comprising at least one cannabinoid and at least one additional therapeutic agent selected from the group consisting of a beta-2 agonist and a muscarinic antagonist. The formulation may be a pMDI formulation further comprising a solvent, a propellant, a co-solvent, a surfactant, and/or a stabilizer, or a dry powder formulation further comprising an excipient. The formulation may be useful in the treatment of obstructive or inflammatory airways diseases.
-
公开(公告)号:US20240325374A1
公开(公告)日:2024-10-03
申请号:US18290772
申请日:2022-07-25
发明人: Ky Van Hoang , John S. Gunn , Christopher Melander , Amy Sorge , Katherine Woolard , Morgan Carpenter
IPC分类号: A61K31/4704 , A61K31/407 , A61P31/04
CPC分类号: A61K31/4704 , A61K31/407 , A61P31/04
摘要: A method of treating or preventing infection by an intracellular pathogen in a subject is described. The method includes administering to the subject a therapeutically effective amount of a composition including KH-1, KH-2, or a derivative and/or a pharmaceutically acceptable salt thereof. A method of treating or preventing bacterial inflammation in a subject is also described. New KH-1 and KH-2 derivatives are also described.
-
3.
公开(公告)号:US20240277692A1
公开(公告)日:2024-08-22
申请号:US18563554
申请日:2022-05-23
申请人: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS , ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI
发明人: Ana MARTÍNEZ GIL , Valle PALOMO RUIZ , Miren Ametsa SÁENZ PEÑA , Adolfo José LÓPEZ DE MUNAIN ARREGI
IPC分类号: A61K31/4704 , A61P21/00
CPC分类号: A61K31/4704 , A61P21/00
摘要: The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I):
or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.-
4.
公开(公告)号:US20240245672A1
公开(公告)日:2024-07-25
申请号:US18441067
申请日:2024-02-14
发明人: Manohar Ratnam
IPC分类号: A61K31/4704 , A61P35/00
CPC分类号: A61K31/4704 , A61P35/00
摘要: A pharmaceutical composition, comprising a compound having chemical structural formula I:
where R1 is selected from the group consisting of: an alkyl group, a heteroalkyl group, an aryl group, a heteroaryl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, a cycloalkyl group, a hetercycloalkyl group, an alkylcycloalkyl group, a heteroalkyl cycloalkyl group, an aralkyl group, a heteroaralkyl group, an alkoxy group, a polar group, an ester and a charged group; a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a pharmaceutically acceptable salt thereof;
where R4′ is H or an alkoxy group; where both R5 and R3′ are OH, and where one or both OH groups is modified as a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof, wherein the prodrug form thereof comprises an ester selected from: an amino acid ester, a phosphate ester, and a sulfonate ester.-
公开(公告)号:US20240122915A1
公开(公告)日:2024-04-18
申请号:US18315633
申请日:2023-05-11
申请人: ACTIVE BIOTECH AB
IPC分类号: A61K31/4704 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/28
CPC分类号: A61K31/4704 , A61K39/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , C07K2317/76
摘要: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
-
公开(公告)号:US11826348B2
公开(公告)日:2023-11-28
申请号:US17361819
申请日:2021-06-29
发明人: Stuart Corr , Timothy James Noakes
IPC分类号: A61K31/40 , A61K47/58 , A61P11/00 , A61K9/00 , A61K31/4704 , A61K31/573 , A61K47/10 , A61K47/24 , A61K45/06 , A61K31/56 , A61K47/12 , A61K47/32
CPC分类号: A61K31/40 , A61K9/008 , A61K31/4704 , A61K31/56 , A61K31/573 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/32 , A61K47/58 , A61P11/00 , A61K31/40 , A61K2300/00 , A61K31/56 , A61K2300/00 , A61K31/4704 , A61K2300/00
摘要: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).
-
公开(公告)号:US20230285573A1
公开(公告)日:2023-09-14
申请号:US17935297
申请日:2022-09-26
发明人: Aseem ANSARI , Pratik SHAH
IPC分类号: A61K47/59 , A61K31/454 , A61K31/4545 , A61K31/4704 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K31/54 , A61K48/00 , A61K47/54 , A61K47/60 , A61K47/22 , A61K47/56 , A61K31/519 , A61K31/517
CPC分类号: A61K47/595 , A61K31/454 , A61K31/4545 , A61K31/4704 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K31/54 , A61K48/0066 , A61K47/54 , A61K47/60 , A61K47/22 , A61K47/56 , A61K31/519 , A61K31/517
摘要: The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
-
公开(公告)号:US20230278962A1
公开(公告)日:2023-09-07
申请号:US18145902
申请日:2022-12-23
IPC分类号: C07D223/16 , C07D215/227 , C07D471/04 , A61P35/00 , A61K45/06 , A61K31/55 , A61K31/4704 , A61K31/4375
CPC分类号: C07D223/16 , A61K31/4375 , A61K31/4704 , A61K31/55 , A61K45/06 , A61P35/00 , C07D215/227 , C07D471/04
摘要: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
-
公开(公告)号:US11730716B2
公开(公告)日:2023-08-22
申请号:US15309176
申请日:2015-05-08
发明人: Stefan Sperl , Franz Obermayr
IPC分类号: A61K31/381 , A61K9/00 , A61K31/196 , A61K47/10 , A61K47/32 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K31/341 , A61K31/44 , A61K31/277 , A61K31/42 , A61K47/38
CPC分类号: A61K31/381 , A61K9/0048 , A61K31/196 , A61K31/277 , A61K31/341 , A61K31/42 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4704 , A61K47/10 , A61K47/32 , A61K47/38
摘要: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
-
公开(公告)号:US20230241044A1
公开(公告)日:2023-08-03
申请号:US17928557
申请日:2021-05-28
发明人: Mukul JAIN , Amit JOHARAPURKAR , Vishal PATEL
IPC分类号: A61K31/4418 , A61K31/5377 , A61K45/06 , A61K31/515 , A61K31/4704 , A61P17/06
CPC分类号: A61K31/4418 , A61K31/515 , A61K31/4704 , A61K31/5377 , A61K45/06 , A61P17/06
摘要: Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical composition comprising compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases.
-
-
-
-
-
-
-
-
-